Jupiter Asset Management Ltd. Invests $25.70 Million in Vertex Pharmaceuticals Incorporated $VRTX
Jupiter Asset Management Ltd. has acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), purchasing 65,619 shares valued at approximately $25.70 million. Other institutional investors have also adjusted their holdings in the pharmaceutical company. Vertex Pharmaceuticals recently reported its quarterly earnings, missing analyst EPS estimates slightly but exceeding revenue expectations.
Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc
Avoro Capital Advisors LLC has increased its stake in Soleno Therapeutics Inc. by purchasing an additional 322,223 shares at $46.3 per share, bringing its total holdings to 2.9 million shares. This move underscores Avoro's confidence in Soleno's biopharmaceutical focus on rare diseases, despite the latter's recent stock decline and low profitability and growth ranks. The transaction highlights continued investor interest in Soleno, with other notable investors including Vanguard Health Care Fund.
Texas Pacific Land Stock Rallies 10% on Record Royalties: Here’s Where the Stock Could Go in 2026
Texas Pacific Land (TPL) stock surged 10.40% to $486.56 after reporting record-breaking financial results, driven by strong oil and gas royalty production and new ventures into AI data centers and water resources. Despite its unique business model and strong financials, TIKR's valuation model suggests the stock is currently overvalued with a projected 4.6% downside from its target price of $463.98, advising caution for investors. The company's expansion into technology infrastructure and its "fortress balance sheet" were highlighted by CEO Ty Glover, but the model indicates these growth prospects are already priced in.
Edwards Lifesciences Stock at $78: Here’s the Analysts’ Bull Case Scenario
Edwards Lifesciences (EW) shares recently rose 4% to $78.92 after a stronger-than-expected Q4 earnings report, with revenue of $1.57 billion driven by strong TAVR and TMTT sales. The company's future looks promising with raised EPS guidance, new product launches, and a shifting market perception from a single-product company to a multi-therapy structural heart platform. Analysts have a mean price target of $96.50, implying a 22% upside, and a DCF model suggests a 70.4% total return by 2030, indicating the stock is potentially undervalued.
Emerson Electric Rose 15% in the Last 6 Months. Here’s Where the Stock Could Go in 2026
Emerson Electric Co. stock has risen 15% in the last six months, trading near $151 per share, driven by strong order trends and improved visibility for 2026 earnings, particularly in automation and software. The company's valuation model suggests a target price of $179, implying an 18.5% upside, largely supported by sustained order growth, expanding Annual Contract Value (ACV), and strength in LNG and power modernization despite weaknesses in China and Europe. The article concludes that Emerson Electric appears modestly undervalued, with its performance in 2026 expected to be driven by automation demand, recurring software revenue, and disciplined execution.
HighTower Advisors LLC Sells 12,332 Shares of Vertex Pharmaceuticals Incorporated $VRTX
HighTower Advisors LLC reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 21.9% in the third quarter, selling 12,332 shares and retaining 44,015 shares valued at $17.24 million. Despite the institutional selling, company revenue grew 9.5% year-over-year to $3.19 billion, although EPS slightly missed estimates at $5.03. Analysts maintain a "Moderate Buy" rating with an average price target of $542.00, while insiders have recently sold shares worth approximately $45.8 million.
Oppenheimer upgrades Vertex Pharmaceuticals (VRTX)
This article reports that Oppenheimer has upgraded its rating for Vertex Pharmaceuticals (VRTX). While the specific details of the upgrade or the new rating are not provided in the snippet, it indicates a positive shift in analyst sentiment towards the company.
Insider Sell: Atkinson Edward Morrow III Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Atkinson Edward Morrow III, Executive Vice President and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc (VRTX), sold 2,848 shares of the company on February 18, 2026. This transaction follows a pattern of insider selling over the past year, with 35 insider sells against 2 buys. Despite the insider sale, Vertex Pharmaceuticals Inc is considered fairly valued with a price-to-GF-Value ratio of 1.
Vertex Casgevy Rollout Tests Gene Editing Role In Vertex Earnings Story
Vertex Pharmaceuticals and CRISPR Therapeutics are initiating patient treatments with their gene-editing therapy, Casgevy, approved for sickle cell disease and beta thalassemia. This rollout is critical for Vertex as it aims to diversify beyond its cystic fibrosis focus, with Casgevy expected to contribute to a projected US$500 million in non-CF product revenue for 2026. Investors will closely monitor the real-world adoption, patient access, and payer response to this high-complexity treatment, as these factors will shape Vertex's future earnings and its position in the broader gene-editing market.
Palatin to test 2 obesity-targeting drugs for PWS in clinical trials this year
Palatin Technologies plans to advance two experimental obesity-targeting drugs, PL7737 and a long-acting peptide, into clinical trials this year for people with Prader-Willi syndrome (PWS) and hypothalamic obesity. These drugs are designed to activate the melanocortin-4 receptor (MC4R) to suppress hunger and are aimed at improving patient tolerability by reducing gastrointestinal side effects and hyperpigmentation, a known side effect of current MC4R agonists. The company expects to submit investigational new drug applications and initiate Phase 1 trials for both candidates in 2026.
Mcrae Capital Management Inc. Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Mcrae Capital Management Inc. increased its stock holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.9% in the third quarter, making it the 17th biggest position for the firm. Other institutional investors also adjusted their stakes in VRTX, while company insiders sold a significant number of shares. Analysts currently rate Vertex Pharmaceuticals as a "Moderate Buy" with an average target price of $542.00.
Cumberland Partners Ltd Has $3.82 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX
Cumberland Partners Ltd significantly reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 79.1% in the third quarter, bringing their total holdings to $3.82 million. Despite this, other institutional investors like Norges Bank and Jennison Associates LLC increased their positions substantially, and analysts have set a "Moderate Buy" consensus rating with an average price target of $542.00. The article also notes recent insider stock sales by executives Charles F. Wagner, Jr. and Jeffrey M. Leiden, amounting to millions of dollars.
Vertex Q4 2025 Earnings: Revenue Beats, Driven by CF Growth & New Launches - News and Statistics
Vertex Pharmaceuticals reported Q4 2025 revenue of $3.19 billion, exceeding analyst forecasts due to strong growth in cystic fibrosis therapies and new product sales in hematology and pain management. Despite a slight miss on adjusted EPS and EBITDA, management highlighted successful international launches and market penetration for CF treatments. The article also touches upon an IndexBox market intelligence report on the global penicillins or streptomycins medicaments industry.
5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q4 Earnings Call
Vertex Pharmaceuticals reported Q4 results that exceeded revenue expectations, driven by cystic fibrosis therapies and new product launches in hematology and pain management. The article highlights five key analyst questions from the earnings call, focusing on topics like product safety, growth drivers, payer access, and clinical benchmarks. Upcoming catalysts include prescription growth for Gernavix, regulatory progress for povitacept, and international expansion efforts.
Assessing Disc Medicine (IRON) Valuation After Recent Share Price Weakness
Disc Medicine (IRON) has experienced recent share price weakness, with a 1-day decline of 2% and larger drops over the past week and month, although longer-term returns remain positive. The company's Price-to-Book (P/B) ratio of 4.2x is below peers but above the broader US biotech industry, indicating a nuanced market valuation for its clinical-stage pipeline. A Discounted Cash Flow (DCF) model suggests a fair value significantly higher than the current trading price, posing a question about market caution versus model optimism.
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call
Vertex Pharmaceuticals reported Q4 results exceeding revenue expectations, driven by cystic fibrosis therapies and new products. Despite missing on adjusted EPS and EBITDA, management emphasized disciplined execution and revenue diversification. The article highlights five key analyst questions and management's responses covering product safety, future growth drivers, payer access, clinical benchmarks, and prescription channel shifts.
Vertex Pharmaceuticals Stock Gains in 2026 on Strong Fundamentals
Vertex Pharmaceuticals has seen its stock gain 8.4% year-to-date in 2026 despite underperforming the broader market over the past year. Analysts remain moderately bullish due to strong fundamentals, pipeline progress, and positive investor sentiment. The company, a major player in biotech with a market cap of $124.8 billion, reported 10% revenue growth in Q4 2025 and is advancing in gene therapies and kidney disease treatments.
Grange Capital LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX
Grange Capital LLC has acquired a new stake of 3,554 shares in Vertex Pharmaceuticals (NASDAQ:VRTX) during Q3, valued at approximately $1.39 million, making it their 27th largest holding. Analysts maintain a "Moderate Buy" rating with a consensus target price of $542.00, despite recent insider sales totaling about $45 million. The company reported quarterly earnings per share of $5.03, slightly missing estimates, but revenue was up 9.5% year-over-year.
Amgen Stock Is Up 14% This Year on Dual Drug Approvals. Can the Rally Hold?
Amgen (AMGN) stock has risen 14% year-to-date, driven by recent FDA and European Commission approvals for its drug UPLIZNA. Despite strong revenue and EPS beats, the company missed significantly on free cash flow in Q4 2025. The article discusses analyst targets, market sentiment, and valuation models, suggesting potential upside if pipeline execution and margin recovery continue, with key catalysts including the Citi Oncology Leadership Summit and initiation of Maritide Phase 3 trials.
PNC Financial Services Group Inc. Has $27.33 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
PNC Financial Services Group Inc. reduced its stake in Vertex Pharmaceuticals (VRTX) by 8.4% in the third quarter, now holding 69,772 shares valued at $27.33 million. Insider selling has been significant, with executives selling shares worth approximately $45.0 million in the past three months. Despite missing EPS estimates slightly, Vertex Pharmaceuticals reported a 9.5% year-over-year revenue increase, and analysts maintain a "Moderate Buy" rating with an average target price of $542.00.
Vertex CEO to discuss strategy at TD Cowen health care conference
Vertex Pharmaceuticals (VRTX) announced that its President and CEO, Reshma Kewalramani, will be participating in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026. A live webcast of the event will be available on the company's website. Vertex is a global biotechnology company focused on developing transformative medicines for serious diseases and conditions.
Narrow-Moat Vertex's Strong CF Sales Drive Growth as Non-CF Portfolio Starts to Gain Traction
Vertex Pharmaceuticals continues to see strong growth driven by its dominant cystic fibrosis (CF) franchise, which can treat about 90% of the CF population. The company maintains a narrow moat due to the efficacy of its CF therapies, strong patents, and lack of competition. Vertex is also developing new pipeline candidates in other indications to further spur future growth beyond its core CF business.
Vertex Pharmaceuticals Stock Jumps 7% Following Oppenheimer Upgrade: Here’s Where the Stock Could Go in 2026
Vertex Pharmaceuticals (VRTX) shares climbed 7% after Oppenheimer upgraded the stock to "Outperform" with a $540 price target, driven by excitement for its emerging renal pipeline, particularly the drug povetacicept. Analysts believe the market is undervaluing Vertex's diversification beyond Cystic Fibrosis into kidney disease, pain management, and gene editing. The TIKR Model suggests the stock is significantly undervalued, projecting a target price of $849 by 2030, with an annualized return of 11.9% due to the pipeline's growth potential and diversification de-risking the stock.
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
Vertex Pharmaceuticals will participate in TD Cowen's 46th Annual Health Care Conference on March 3, 2026. Reshma Kewalramani, President and CEO, will conduct a fireside chat at 9:10 a.m. ET, which will be webcast live on the company's investor relations website. Vertex is a biotechnology company focused on developing transformative medicines for serious diseases.
10 Health Care Stocks With Whale Alerts In Today's Session
This article highlights unusual options activity, known as "whale alerts," for ten health care stocks: AbbVie (ABBV), Abbott Laboratories (ABT), Amgen (AMGN), McKesson (MCK), Madrigal Pharmaceuticals (MDGL), Molina Healthcare (MOH), Merck & Co (MRK), Intellia Therapeutics (NTLA), UnitedHealth Group (UNH), and Vertex Pharmaceuticals (VRTX). It details specific call and put option trades, including strike prices, expiration dates, sentiment, and trade volumes, to help traders identify potential opportunities. The report explains key options terminology for better understanding of these alerts.
HC Wainwright & Co. Raises Vertex Pharmaceuticals (VRTX) Price Target | VRTX Stock News
HC Wainwright & Co. has increased its price target for Vertex Pharmaceuticals (VRTX) to $591.00 from $518.00, maintaining a "Buy" rating. This adjustment reflects continued confidence in the company, a global biotechnology firm known for its cystic fibrosis drugs and diversified portfolio including gene-editing therapy and non-opioid pain medication. Analysts anticipate an average target price of $525.59 for VRTX, indicating an "Outperform" status.
Vanguard Group Inc. Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX
Vanguard Group Inc. increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 1.0% in the third quarter, bringing its total ownership to 24,216,865 shares valued at approximately $9.48 billion. Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $537.05, despite recent insider stock sales totaling $45 million and a slight EPS miss in the last quarter. The company's revenue increased by 9.5% to $3.19 billion, and it holds a market capitalization of $124.70 billion.
Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday
This article summarizes recent analyst rating changes for ten different companies, including upgrades, downgrades, and price target adjustments. Notably, Needham raised the price target for Micron Technology (MU) from $380 to $450, maintaining a Buy rating. Other firms like Rosenblatt, Piper Sandler, Mizuho, HC Wainwright & Co., Raymond James, BTIG, Truist Securities, Morgan Stanley, and Ascendiant Capital also provided updated forecasts for various stocks.
Alpha Thalassemia Market to Reach US$ 1.9 Billion by 2031 | North
The global Alpha Thalassemia Market is projected to reach US$ 1.9 billion by 2031, growing from US$ 1.1 billion in 2022 at a CAGR of 7.4%. North America is expected to lead with a 35% market share, driven by advanced healthcare infrastructure and genetic testing. Key market drivers include the increasing prevalence of genetic blood disorders, diagnostic advancements, and growing awareness, with major companies like Agios Pharmaceuticals, Actis, and Novartis Pharmaceuticals Corporation shaping the market through therapeutic innovation and expanded access.
NEOS Investment Management LLC Purchases 37,296 Shares of Vertex Pharmaceuticals Incorporated $VRTX
NEOS Investment Management LLC increased its stake in Vertex Pharmaceuticals Incorporated by 48.9% in the 3rd quarter, purchasing an additional 37,296 shares. Other institutional investors also adjusted their positions in VRTX. The article also details recent insider stock sales, analyst ratings, and the company's financial performance.
Skandinaviska Enskilda Banken AB publ Has $60.39 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Skandinaviska Enskilda Banken AB publ reduced its stake in Vertex Pharmaceuticals by 12.7% in the third quarter, now holding 154,248 shares valued at approximately $60.39 million. Other institutional investors like Vanguard Group Inc. increased their holdings, with institutional ownership collectively at 90.96%. Despite a slight earnings per share miss, the company's revenue grew, and analysts maintain a "Moderate Buy" rating with a consensus target price of $537.05.
Public Sector Pension Investment Board Has $8.78 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX
The Public Sector Pension Investment Board increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 13.9% to 22,418 shares, valued at approximately $8.78 million. This comes as company insiders have been net sellers, with significant share sales totaling over $45 million in the last 90 days. Despite missing EPS estimates, current analyst ratings suggest a "Moderate Buy" consensus with a price target near $537.05.
Hypoglycemia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Amphastar Pharma, Eiger BioPharma, Eli Lilly, Novo Nordisk, Xeris Pharma
DelveInsight's "Hypoglycemia Pipeline Insight, 2025" report outlines the current clinical development landscape for hypoglycemia, identifying over 10 companies working on 12+ treatment therapies. The report details pipeline products from pre-clinical to marketed phases, including their mechanisms of action, clinical study status, and product development activities. Key companies mentioned include Twist Bioscience, Eiger BioPharmaceuticals, Eli Lilly, and Novo Nordisk, with therapies like Avexitide and MBX 1416 progressing through clinical trials.
Why Vertex Pharmaceuticals (VRTX) Is Up 6.0% After Profit Rebound And Non-CF Pipeline Update - And What's Next
Vertex Pharmaceuticals reported strong full-year 2025 results with a revenue increase to US$12.00 billion and a significant rebound to a US$3.95 billion net profit. The company's 2026 guidance anticipates growing contributions from non-cystic fibrosis products like CASGEVY and JOURNAVX, alongside a new collaboration in autoimmune diseases. This shift towards non-CF revenue and improved profitability is reshaping Vertex's investment narrative and risk profile.
Top-Rated Stocks: Vertex Pharmaceuticals Sees Composite Rating Climb To 96
Vertex Pharmaceuticals (VRTX) recently saw its IBD SmartSelect Composite Rating increase from 87 to 96, indicating strong performance against other stocks based on key selection criteria. The stock is currently forming a consolidation pattern with a specified buy point. This upgrade follows earlier improvements in its Relative Strength Rating, highlighting its improving price performance.
Zions Bancorporation National Association UT Buys 9,452 Shares of Vertex Pharmaceuticals Incorporated $VRTX
Zions Bancorporation National Association UT significantly increased its stake in Vertex Pharmaceuticals, purchasing 9,452 shares to hold a total of 9,638 shares valued at approximately $3.78 million. Vertex Pharmaceuticals reported Q4 EPS of $5.03 and revenues of $3.19 billion, exceeding most forecasts, leading to multiple analyst price target increases and a consensus "Moderate Buy" rating. Despite recent insider selling, institutional investors hold a substantial 90.96% of the stock.
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
Moderna (MRNA) shares rose 5.3% on Friday, February 13, as investors renewed interest in large-cap biotech companies, highlighting confidence in its vaccine platform and long-term growth narrative. The gain, alongside peers Adagene Inc. (ADAG) and Vertex Pharmaceuticals Incorporated (VRTX), suggests a broader recalibration in risk appetite towards innovative healthcare leaders. Institutional buying and short-covering appear to have contributed to the stock's strength, indicating Wall Street's reception to biotech firms with durable platforms.
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
Sanofi has reportedly made a significantly revised bid for Ocular Therapeutix, ahead of the biotech company's crucial Phase 3 SOL-1 trial results. The acquisition could reshape the retinal disease market, with Ocular Therapeutix's AXPAXLI therapy holding the potential to offer superior, less frequent treatment for wet age-related macular degeneration. This aggressive move by Sanofi aims to preempt a valuation surge and re-establish its presence in the ophthalmology sector it previously exited.
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 3.9% during the third quarter. Several other institutional investors also adjusted their holdings in the pharmaceutical company, which reported mixed Q4 earnings but received multiple analyst upgrades. Insider selling was also noted, despite a generally positive outlook from analysts on revenue and pipeline diversification.
Cibc World Market Inc. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Cibc World Market Inc. significantly reduced its stake in Vertex Pharmaceuticals (VRTX) by 73.3%, selling over 22,000 shares but still retaining shares valued at $3.23 million. This comes despite Vertex's Q4 revenue largely meeting expectations and analysts generally raising price targets, though the company did experience a slight EPS miss and notable insider selling. Institutional ownership remains high at nearly 91%.
Vertex Expands Beyond Cystic Fibrosis With WuXi Autoimmune T Cell Pact
Vertex Pharmaceuticals has entered into an agreement with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases, marking a strategic expansion beyond its core cystic fibrosis and gene therapy pipeline. This deal gives Vertex exclusive rights to develop and commercialize the preclinical therapy, leveraging its strong financial position and R&D capabilities. While this diversification offers significant growth potential, it also introduces risks related to high R&D costs and competition in an established autoimmune market.
Vertex Expands Beyond Cystic Fibrosis With WuXi Autoimmune T Cell Pact
Vertex Pharmaceuticals has partnered with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases, marking a strategic expansion beyond its core cystic fibrosis and gene therapy pipeline. This move allows Vertex to leverage its strong cash flow and scientific expertise in a new therapeutic area, despite potential R&D challenges and established competition. The company's financial performance includes US$12.0 billion revenue and US$3.95 billion net income in 2025.
Crispr Therapeutics Stock Target Raised Amidst Positive Momentum
Crispr Therapeutics (CRSP) is experiencing positive momentum due to promising clinical trial results for its Casgevy therapy, leading analysts like Chardan and Evercore ISI to raise their price targets to $76 and $74 respectively, while maintaining "Buy" ratings. Despite current negative profitability margins, the company shows strong liquidity and growth potential, with institutional confidence echoed by ARK Investment's acquisition of CRSP shares. The stock's recent performance reflects robust buying interest, though investors are advised to monitor support and resistance levels.
Shell Asset Management Co. Sells 10,515 Shares of Vertex Pharmaceuticals Incorporated $VRTX
Shell Asset Management Co. has decreased its stake in Vertex Pharmaceuticals (VRTX) by 61.2%, selling 10,515 shares. Despite this, other institutional investors have increased their holdings, and analysts maintain a "Moderate Buy" rating with an average target price of $537.05. The company recently reported Q4 revenue of $3.19 billion, exceeding analyst estimates, although EPS slightly missed expectations.
Prospera Financial Services Inc Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Prospera Financial Services Inc. significantly reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 78.2% in the third quarter, selling 8,002 shares and retaining 2,233 shares valued at approximately $875,000. This comes as Vertex reported a slight EPS miss for Q4 but met revenue expectations and provided in-line FY2026 guidance. Despite recent insider selling, analysts maintain a largely positive outlook with a consensus price target near $537.
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update
Solid Biosciences (NASDAQ: SLDB) recently presented updates on its gene therapy pipeline, focusing on its Duchenne Muscular Dystrophy (DMD) program, SGT-003, and early progress in Friedreich’s ataxia (FA). The company announced alignment with the FDA for a registration pathway for SGT-003, aiming for accelerated approval, and plans a double-blind, placebo-controlled DMD study outside the U.S. with first pediatric dosing expected within 90 days. Solid Biosciences also shared initial positive anecdotal signals from the first Friedreich's ataxia patient treated with a dual-route administration, with plans to dose more patients and release data later this year.
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Aberdeen Group plc
Aberdeen Group plc increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 9.3% in the third quarter, now owning 314,889 shares valued at $123.3 million. This comes as Vertex Pharmaceuticals reported quarterly earnings that narrowly missed analyst estimates but showed revenue growth of 9.5% year-over-year. The article also details other institutional investor activity, insider selling, recent analyst ratings, and outlines both positive and negative sentiments impacting the company, including strong product momentum, analyst upgrades, and an EPS miss with insider sales.
Is Vertex Pharmaceuticals (VRTX) Still Attractive After Strong Multi Year Share Price Gains
Vertex Pharmaceuticals (VRTX) has seen significant share price gains over multiple years, prompting a valuation analysis. Simply Wall St's Discounted Cash Flow model suggests the stock is undervalued by 36.0% at its current price of US$491.47, with an intrinsic value of about $767.46 per share. However, its P/E ratio of 31.54x is higher than the biotech industry average, screening it as somewhat overvalued by that metric.
CRISPR Therapeutics (CRSP) Stock: Why Bad Earnings Sparked a 9% Rally
CRISPR Therapeutics (CRSP) stock unexpectedly rallied 9.2% despite missing Q4 earnings estimates, reporting only $864,000 in revenue. The surge was driven by partner Vertex Pharmaceuticals' optimistic 2026 guidance, projecting over $500 million in non-cystic fibrosis product revenue, largely from increased Casgevy infusions. Casgevy, an FDA-approved gene-editing treatment, saw almost triple the patient initiations in 2025 compared to 2024, with expanding reimbursement coverage in the US, Europe, and the Middle East, signaling strong future revenue potential.
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Pacific Biosciences (PACB)
Analysts from TD Cowen have issued bullish ratings on two healthcare companies: Vertex Pharmaceuticals (VRTX) and Pacific Biosciences (PACB). Phil Nadeau maintained a "Buy" rating for Vertex Pharmaceuticals with a price target of $525.00, while Daniel Brennan reiterated a "Buy" rating for Pacific Biosciences with a $3.00 price target. Both analysts are highly rated in the healthcare sector, and their projections suggest potential upside for these stocks.
